Pegivirus Detection in Cerebrospinal Fluid from Patients with Central Nervous System Infections of Unknown Etiology in Brazil by Viral Metagenomics

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
CARMONA, Rita de Cassia Compagnoli
CILLI, Audrey
REIS, Fabricio Caldeira
LEAL, Elcio
SANTOS, Fabiana Cristina Pereira dos
MACHADO, Braulio Caetano
LOPES, Cristina Santiago
AFONSO, Ana Maria Sardinha
TIMENETSKY, Maria do Carmo Sampaio Tavares
Citação
MICROORGANISMS, v.12, n.1, article ID 19, 13p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Metagenomic next-generation sequencing (mNGS) methodology serves as an excellent supplement in cases where diagnosis is challenging to establish through conventional laboratory tests, and its usage is increasingly prevalent. Examining the causes of infectious diseases in the central nervous system (CNS) is vital for understanding their spread, managing outbreaks, and effective patient care. In a study conducted in the state of Sao Paulo, Brazil, cerebrospinal fluid (CSF) samples from 500 patients with CNS diseases of indeterminate etiology, collected between 2017 and 2021, were analyzed. Employing a mNGS approach, we obtained the complete coding sequence of Pegivirus hominis (HPgV) genotype 2 in a sample from a patient with encephalitis (named IAL-425/BRA/SP/2019); no other pathogen was detected. Subsequently, to determine the extent of this virus's presence, both polymerase chain reaction (PCR) and/or real-time PCR assays were utilized on the entire collection. The presence of the virus was identified in 4.0% of the samples analyzed. This research constitutes the first report of HPgV detection in CSF samples in South America. Analysis of the IAL-425 genome (9107 nt) revealed a 90% nucleotide identity with HPgV strains from various countries. Evolutionary analyses suggest that HPgV is both endemic and extensively distributed. The direct involvement of HPgV in CNS infections in these patients remains uncertain.
Palavras-chave
metagenomic, pegivirus human, central nervous system infections, cerebrospinal fluid
URI
https://observatorio.fm.usp.br/handle/OPI/59133
Referências
  1. Alcalde R, 2010, VIRUS RES, V151, P148, DOI 10.1016/j.virusres.2010.04.008
  2. Altan E, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080793
  3. Balcom EF, 2018, ANN NEUROL, V84, P781, DOI 10.1002/ana.25343
  4. Bezerra RD, 2022, VIRUS RES, V311, DOI 10.1016/j.virusres.2022.198689
  5. Bezerra RD, 2021, BLOOD TRANSFUS-ITALY, V19, P93, DOI 10.2450/2020.0027-20
  6. Bezerra RD, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2019.102697
  7. Bonsall D, 2016, EMERG INFECT DIS, V22, P671, DOI 10.3201/eid2204.151812
  8. Bukh J, 1998, J INFECT DIS, V177, P855, DOI 10.1086/515255
  9. Bukowska-Osko I, 2018, EMERG INFECT DIS, V24, P1785, DOI 10.3201/eid2410.180161
  10. Cebriá-Mendoza M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13112322
  11. Cebriá-Mendoza M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86427-4
  12. Charrel RN, 1999, BIOCHEM BIOPH RES CO, V255, P432, DOI 10.1006/bbrc.1999.0205
  13. Chivero ET, 2015, J GEN VIROL, V96, P1521, DOI 10.1099/vir.0.000086
  14. da Costa BK, 2020, J PEDIAT-BRAZIL, V96, P12, DOI 10.1016/j.jped.2019.07.006
  15. Da Mota LD, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8048670
  16. Da Mota LD, 2019, J MED VIROL, V91, P31, DOI 10.1002/jmv.25291
  17. Deng XT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv002
  18. Dias J.Z.C., 2018, Influencia do Pegivirus Humano (HPgV) na Medula Ossea: Impacto Clinico e Tropismo Viral
  19. Erker JC, 1996, J GEN VIROL, V77, P2713, DOI 10.1099/0022-1317-77-11-2713
  20. Feng Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021151
  21. Fridholm H, 2016, J CLIN VIROL, V77, P5, DOI 10.1016/j.jcv.2016.01.013
  22. George SL, 2003, VIROLOGY, V316, P191, DOI 10.1016/S0042-6822(03)00585-3
  23. Hardie D, 2017, J CLIN VIROL, V91, P58, DOI 10.1016/j.jcv.2017.04.007
  24. Holmes EC, 2008, ANNU REV MICROBIOL, V62, P307, DOI 10.1146/annurev.micro.62.081307.162912
  25. Ide W, 2021, PHYS MED REH CLIN N, V32, P477, DOI 10.1016/j.pmr.2021.02.004
  26. Jordier F, 2019, J MED VIROL, V91, P38, DOI 10.1002/jmv.25290
  27. Katayama K, 1998, ARCH VIROL, V143, P1063, DOI 10.1007/s007050050356
  28. Kincaid O, 2006, CURR NEUROL NEUROSCI, V6, P469, DOI 10.1007/s11910-006-0048-1
  29. Kohil A, 2021, ARCH VIROL, V166, P335, DOI 10.1007/s00705-020-04891-1
  30. Kriesel JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031886
  31. Lau JSY, 2017, NEW MICROBIOL, V40, P212
  32. Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
  33. Liu Z, 2016, EPIDEMIOL INFECT, V144, P106, DOI 10.1017/S0950268815001326
  34. Maximova OA, 2018, ANNU REV VIROL, V5, P255, DOI 10.1146/annurev-virology-092917-043439
  35. Miyoshi IC, 2023, SEMIN ULTRASOUND CT, V44, P424, DOI 10.1053/j.sult.2023.03.015
  36. Mrzljak Anna, 2022, World J Transplant, V12, P1, DOI 10.5500/wjt.v12.i1.1
  37. Muerhoff AS, 2005, J GEN VIROL, V86, P1729, DOI 10.1099/vir.0.80854-0
  38. Naito H, 2000, J GEN VIROL, V81, P189, DOI 10.1099/0022-1317-81-1-189
  39. Nunes PF, 2023, VIRUSES-BASEL, V15, DOI 10.3390/v15091892
  40. Okamoto H, 1997, J GEN VIROL, V78, P737, DOI 10.1099/0022-1317-78-4-737
  41. Olausson J, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-07260-x
  42. Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
  43. Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
  44. Saito T, 1999, HEPATOL RES, V13, P221, DOI 10.1016/S1386-6346(98)00095-3
  45. Samadi M, 2022, VIROL J, V19, DOI 10.1186/s12985-022-01769-3
  46. Santos LM, 2017, INT J GYNECOL OBSTET, V138, P113, DOI 10.1002/ijgo.12175
  47. Savassi-Ribas F, 2020, J MED VIROL, V92, P2961, DOI 10.1002/jmv.25764
  48. Shao L, 1996, BIOCHEM BIOPH RES CO, V228, P785, DOI 10.1006/bbrc.1996.1732
  49. SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
  50. Slavov SN, 2019, TRANSFUS APHER SCI, V58, P174, DOI 10.1016/j.transci.2019.01.002
  51. Stapleton JT, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.887760
  52. Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
  53. Takahashi K, 1997, INT HEPATOL COMMUN, V6, P253, DOI 10.1016/S0928-4346(97)00355-1
  54. Taklual W, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1161-5
  55. Trifinopoulos J, 2016, NUCLEIC ACIDS RES, V44, pW232, DOI 10.1093/nar/gkw256
  56. Tuddenham R, 2020, DIAGN MICR INFEC DIS, V96, DOI 10.1016/j.diagmicrobio.2019.114898
  57. Valyraki N, 2023, REV NEUROL-FRANCE, V179, P361, DOI 10.1016/j.neurol.2022.06.011
  58. Wang HL, 1997, J INFECT DIS, V175, P1229, DOI 10.1086/593676
  59. Wilson MR, 2019, NEW ENGL J MED, V380, P2327, DOI 10.1056/NEJMoa1803396
  60. Wu Z, 2020, J VIROL, V94, DOI 10.1128/JVI.01150-20
  61. Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000
  62. Yang N, 2020, VOX SANG, V115, P107, DOI 10.1111/vox.12876
  63. Ye J, 2006, NUCLEIC ACIDS RES, V34, pW6, DOI 10.1093/nar/gkl164
  64. Yu YQ, 2022, VIRULENCE, V13, P324, DOI 10.1080/21505594.2022.2029328
  65. Zimmerman J, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2257

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP